13 studies found for:    S1115
Show Display Options
Rank Status Study
1 Active, not recruiting Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy
Conditions: Pancreatic Acinar Cell Carcinoma;   Pancreatic Ductal Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer
Interventions: Drug: Akt Inhibitor MK2206;   Drug: Selumetinib;   Drug: Oxaliplatin;   Drug: Fluorouracil
2 Completed
Has Results
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes
Condition: Stroke
Interventions: Drug: Aggrenox;   Drug: Clopidogrel placebo;   Drug: Micardis;   Drug: Aggrenox placebo;   Drug: Clopidogrel;   Drug: Micardis placebo
3 Enrolling by invitation Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis
Conditions: Liver Cirrhosis;   Fibrosis;   Liver Disease;   Digestive System Disease
Interventions: Biological: conventional therapy plus MenSC transplantation;   Drug: Conventional therapy plus placebo treatment
4 Completed Comparison of Two Identical NN1250 Formulations in Healthy Volunteers
Conditions: Diabetes;   Healthy
Intervention: Drug: insulin degludec
5 Completed
Has Results
Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study
Condition: Depressive Disorder, Major
Intervention: Drug: Vortioxetine
6 Recruiting Efficacy of Tranexamic Acid in Reducing Blood Loss During and After Caesarean Section
Condition: Hemorrhage of Cesarean Section and/or Perineal Wound
Interventions: Drug: Tranexamic Acid;   Drug: Glucose
7 Completed Effect of Different Doses of SAR110894D on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
Condition: Dementia Alzheimer's Type
Interventions: Drug: SAR110894D;   Drug: placebo
8 Active, not recruiting Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
Conditions: Childhood Solid Neoplasm;   Recurrent Childhood Anaplastic Astrocytoma;   Recurrent Childhood Anaplastic Oligoastrocytoma;   Recurrent Childhood Anaplastic Oligodendroglioma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Diffuse Astrocytoma;   Recurrent Childhood Fibrillary Astrocytoma;   Recurrent Childhood Gemistocytic Astrocytoma;   Recurrent Childhood Giant Cell Glioblastoma;   Recurrent Childhood Glioblastoma;   Recurrent Childhood Gliomatosis Cerebri;   Recurrent Childhood Gliosarcoma;   Recurrent Childhood Oligoastrocytoma;   Recurrent Childhood Oligodendroglioma;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Pleomorphic Xanthoastrocytoma;   Recurrent Childhood Protoplasmic Astrocytoma;   Recurrent Childhood Subependymal Giant Cell Astrocytoma;   Recurrent Childhood Visual Pathway Glioma
Interventions: Biological: Trebananib;   Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
9 No longer available An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.
Condition: HIV Infections
Intervention: Drug: Tipranavir
10 Completed
Has Results
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium;   Drug: placebo
11 Recruiting Reference Values for Plasma Catechols
Conditions: Catecholamine;   Healthy Volunteers;   Normal Physiology
Intervention:
12 Completed
Has Results
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
Conditions: Atrial Fibrillation;   Stroke
Interventions: Drug: warfarin;   Drug: Dabigatran dose 1;   Drug: Dabigatran dose 2
13 Recruiting A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Ertugliflozin (5 mg);   Drug: Ertugliflozin (10 mg);   Drug: Placebo to Ertuglifozin;   Drug: Metformin;   Drug: Placebo to Metformin

Indicates status has not been verified in more than two years